Jason P Lott1, Jade Wititsuwannakul2, Julie J Lee3, Stephan Ariyan4, Deepak Narayan4, Harriet H Kluger5, Rossitza Lazova6. 1. Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut; Section of Dermatology, Veterans Administration Connecticut Healthcare System, West Haven, Connecticut. 2. Department of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, Thailand. 3. University of Southern California, Keck School of Medicine, Los Angeles, California. 4. Yale Cancer Center, New Haven, Connecticut; Section of Plastic and Reconstructive Surgery, Department of Surgery, Yale University School of Medicine, New Haven, Connecticut. 5. Yale Cancer Center, New Haven, Connecticut; Section of Medical Oncology, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut. 6. Yale Cancer Center, New Haven, Connecticut; Department of Dermatology, Yale University School of Medicine, New Haven, Connecticut. Electronic address: rossitza.lazova@yale.edu.
Abstract
BACKGROUND: Spitz nevi and Spitzoid malignant melanomas are uncommon and may be difficult to distinguish histopathologically. Identification of clinical features associated with these lesions may aid in diagnosis. OBJECTIVE: We sought to identify clinical characteristics associated with Spitz nevi and Spitzoid malignant melanomas. METHODS: We conducted a retrospective cohort study of Spitz nevi and Spitzoid malignant melanomas from the Yale University Spitzoid Neoplasm Repository diagnosed from years 1991 through 2008. Descriptive statistics and multivariate logistic regression were used to compare select patient- and tumor-level factors associated with each lesion. RESULTS: Our cohort included 484 Spitz nevi and 54 Spitzoid malignant melanomas. Spitz nevi were more common (P = .03) in females (65%; n = 316) compared with Spitzoid malignant melanomas (50%; n = 27), occurred more frequently in younger patients (mean age at diagnosis 22 vs 55 years; P < .001), and more likely presented as smaller lesions (diameter 7.6 vs 10.5 mm; P < .001). Increasing age (odds ratio 1.16, 95% CI [1.09, 1.14]; P< .001) and male gender (odds ratio 2.77, 95% CI [1.17, 6.55]; P< .02) predicted Spitzoid malignant melanoma diagnosis. LIMITATIONS: Small sample size, unmeasured confounding, and restriction to a single institution may limit the accuracy and generalizability of our findings. CONCLUSIONS: Age and gender help predict diagnosis of Spitz nevi and Spitzoid malignant melanomas.
BACKGROUND: Spitz nevi and Spitzoid malignant melanomas are uncommon and may be difficult to distinguish histopathologically. Identification of clinical features associated with these lesions may aid in diagnosis. OBJECTIVE: We sought to identify clinical characteristics associated with Spitz nevi and Spitzoid malignant melanomas. METHODS: We conducted a retrospective cohort study of Spitz nevi and Spitzoid malignant melanomas from the Yale University SpitzoidNeoplasm Repository diagnosed from years 1991 through 2008. Descriptive statistics and multivariate logistic regression were used to compare select patient- and tumor-level factors associated with each lesion. RESULTS: Our cohort included 484 Spitz nevi and 54 Spitzoid malignant melanomas. Spitz nevi were more common (P = .03) in females (65%; n = 316) compared with Spitzoid malignant melanomas (50%; n = 27), occurred more frequently in younger patients (mean age at diagnosis 22 vs 55 years; P < .001), and more likely presented as smaller lesions (diameter 7.6 vs 10.5 mm; P < .001). Increasing age (odds ratio 1.16, 95% CI [1.09, 1.14]; P< .001) and male gender (odds ratio 2.77, 95% CI [1.17, 6.55]; P< .02) predicted Spitzoid malignant melanoma diagnosis. LIMITATIONS: Small sample size, unmeasured confounding, and restriction to a single institution may limit the accuracy and generalizability of our findings. CONCLUSIONS: Age and gender help predict diagnosis of Spitz nevi and Spitzoid malignant melanomas.
Authors: Alma C Berlingeri-Ramos; Adisbeth Morales-Burgos; Jorge L Sánchez; Elena M Nogales Journal: Am J Dermatopathol Date: 2010-05 Impact factor: 1.533
Authors: Gerardo Ferrara; Giuseppe Argenziano; H Peter Soyer; Sergio Chimenti; Arturo Di Blasi; Giovanni Pellacani; Ketty Peris; Domenico Piccolo; Pietro Rubegni; Stefania Seidenari; Stefania Staibano; Iris Zalaudek; Gaetano De Rosa Journal: Arch Dermatol Date: 2005-11
Authors: Anna Maria Cesinaro; Moira Foroni; Pamela Sighinolfi; Mario Migaldi; Gian Paolo Trentini Journal: Am J Dermatopathol Date: 2005-12 Impact factor: 1.533
Authors: D W Bartenstein; J M Fisher; C Stamoulis; C Weldon; J T Huang; S E Gellis; M G Liang; B Schmidt; E B Hawryluk Journal: Br J Dermatol Date: 2019-02-10 Impact factor: 9.302
Authors: Anna Eisenstein; Izabela P Panova; Hye J Chung; Lynne J Goldberg; Qing Zhang; Rossitza Lazova; Jag Bhawan; Klaus J Busam; James T Symanowski; Rhoda M Alani; Byungwoo Ryu Journal: Melanoma Res Date: 2018-02 Impact factor: 3.599
Authors: Rossitza Lazova; Erin H Seeley; Heinz Kutzner; Richard A Scolyer; Glynis Scott; Lorenzo Cerroni; Isabella Fried; Milena E Kozovska; Arlene S Rosenberg; Victor G Prieto; Bahig M Shehata; Megan M Durham; Gina Henry; Jose L Rodriguez-Peralto; Erica Riveiro-Falkenbach; Jochen T Schaefer; Richard Danialan; Sylvie Fraitag; Sonja Vollenweider-Roten; Alireza Sepehr; Martin Sangueza; Nouf Hijazi; Yamile Corredoira; Rachel Kowal; Olga M Harris; Francisco Bravo; Alan S Boyd; Ralitza Gueorguieva; Richard M Caprioli Journal: J Am Acad Dermatol Date: 2016-08-05 Impact factor: 11.527
Authors: Sarah Benton; Andrew Roth; Ayesha U Khan; Jeffrey Zhao; Daniel Kim; Elsy V Compres; Annette M Wagner; Lacey L Kruse; Bin Zhang; Pedram Gerami Journal: Pediatr Dermatol Date: 2022-02-21 Impact factor: 1.997